BioCentury
ARTICLE | Company News

JHL, Sanofi deal

December 16, 2016 5:20 PM UTC

JHL granted Sanofi exclusive, Chinese development and commercialization rights to biosimilar rituximab (JHL1101). JHL will receive $21 million up front and is eligible for up to $236 million in milestones, plus royalties. Sanofi also invested NT$2.6 billion ($79.6 million) in JHL by purchasing 28.3 million shares at NT$90 in a separate private placement. The deal also includes options for rights to JHL’s biosimilar bevacizumab (JHL1149), biosimilar trastuzumab (JHL1188) and biosimilar adalimumab (JHL1228)...